News & Updates
Showing Oncology articles
Showing
Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.
Intensive rehab benefits lung cancer patients undergoing surgery
A rehabilitation programme comprising intensive perioperative pulmonary rehabilitation (PR) and standard of care (SC) led to improved exercise capacity and tolerance in individuals with early-stage non-small-cell lung cancer (NSCLC) who are undergoing lung resection, the PUREAIR trial suggests.
Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.
5α-reductase inhibitors help reduce SARS-CoV-2 infection risk in men
Use of 5α-reductase inhibitors (5ARIs) appears to lower the risk of community-acquired infection with SARS-CoV-2 in men without prostate cancer, according to a study, noting that treatment with this drug class can help ease the burden of COVID-19.
